Preview

Комплексные проблемы сердечно-сосудистых заболеваний

Расширенный поиск

БИОЛОГИЧЕСКАЯ ИСКУССТВЕННАЯ ПЕЧЕНЬ

https://doi.org/10.17802/2306-1278-2014-4-70-79

Полный текст:

Аннотация

Печеночная недостаточность является важнейшим жизнеугрожающим состоянием, ассоциирующимся с высочайшей степенью смертности. В обзоре приводятся основные направления по искусственному замещению функций печени, делается акцент на теоретических и практических возможностях создания биологической искусственной печени, разделов оптимизации: модификации мембран, выбора клеток для протезирования функции и создания благоприятной биологической среды для функционирования клеток.

Об авторах

Е. В. Григорьев
Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний», Кемерово
Россия


Г. П. Плотников
Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний», Кемерово
Россия

ведущий научный сотрудник лаборатории критических состояний

Адрес для переписки:
Г. П. Плотников, 650002, г. Кемерово, Сосновый бульвар, д. 6. Тел: +7 (3842) 64-33-08



Д. Л. Шукевич
Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний», Кемерово
Россия


А. С. Головкин
Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний», Кемерово
Россия


Список литературы

1. A biological extracorporeal metabolic device for hepatic support / I. Koshino [et al.] // Trans. Amer. Soc. Artif. Intern. Organs. 1975. Vol. 21. P. 492.

2. A comparative study of proliferation and hepatic differentiation of human adipose-derived stem cells / R. Coradeghini [et al.] // Cells Tissues Organs. 2010. Vol. 191. P. 466–477.

3. A reversibly immortalized human hepatocyte cell line as a source of hepatocyte-based biological support / N. Kobayashi [et al.] // Addict Biol. 2001. Vol. 6. P. 293–300.

4. A tightly regulated immortalized human fetal hepatocyte cell line to develop a bioartificial liver / N. Kobayashi [et al.] // Transplant. Proc. 2001. Vol. 33. P. 1948–1949.

5. Adham M. Extracorporeal liver support: waiting for the deciding vote // ASAIO J. 2003. Vol. 49. P. 621–632.

6. Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes / A. Banas [et al.] // Hepatology. 2007. Vol. 46. P. 219–228.

7. Alginate-encapsulated HepG2 cells in a fluidized bed bioreactor maintain function in human liver failure plasma / S. M. Coward [et al.] // Artif. Organs. 2009. Vol. 33. P. 1117–1126.

8. Alginate-encapsulated human hepatoblastoma cells in an extracorporeal perfusion system improve some systemic parameters of liver failure in a xenogeneic model / T. M. Rahman [et al.] // Artif. Organs. 2004. Vol. 28 P. 476–482.

9. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review / L. L. Jaergard [et al.] // JAMA. 2003. Vol. 289. P. 217–222.

10. Artificial liver support devices for fulminant liver failure / A. Sechser [et al.] // Clin. Liver. Dis. 2001. Vol. 5. P. 415–430.

11. Bioartificial liver support: report of the longest continuous treatment with human hepatocytes / J. M. Millis [et al.] // Transplant. Proc. 2001. Vol. 33. P. 1935.

12. Biochemical and molecular characterization of hepatocytelike cells derived from human bone marrow mesenchymal stem cells on a novel three-dimensional biocompatible nanofibrous scaffold / S. Kazemnejad [et al.] // J. Gastroenterol. Hepatol. 2009. Vol. 24. P. 278–287.

13. Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver / M. P. van de Kerkhove [et al.] // Cell Transplant. 2003. Vol. 12. P. 563–568.

14. Brunner G., Holloway C. J., Lösgen H. The application of immobilized enzymes in an artificial liver support system // Artif. Organs. 1979. Vol. 3. P. 27–30.

15. Brunner G., Tegtimeier F. Enzymatic detoxification using lipophilic hollow fiber membranes // Artif. Organs. 1984. Vol. 8. P. 161–166.

16. Caron J. M., Bissel D. M. Extracellular matrix induces albumin gene expression in cultured rat hepatocytes // Hepatology. 1989. Vol. 10 (4). P. 636.

17. Carpentier B., Gautier A., Legallais C. Artificial and bioartificial liver devices: present and future // Gut. 2009. Vol. 58. P. 1690–1702.

18. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis / C. Natanson [et al.] // JAMA. 2008. Vol. 299. P. 2304–2312.

19. Cell-free supernatant from hepatocyte cultures improves survival of rats with chemically induced acute liver failure / P. LaPlante-O’Neill [et al.] // J. Surg. Res. 1982. Vol. 32. P. 347.

20. Cells for bioartificial liver devices: the human hepatomaderived cell line C3A produces urea but does not detoxify ammonia / D. Mavri-Damelin [et al.] // Biotechnol. Bioeng. 2008. Vol. 99. P. 644–651.

21. Chamuleau R. A., Deurholt T., Hoekstra R. Which are the right cells to be used in a bioartificial liver? // Metab. Brain. Dis. 2005. Vol. 20. P. 327–335.

22. Chamuleau R. A. Future of bioartificial liver support // World J. Gastrointest. Surg. 2009. Vol. 1. P. 21–25.

23. Chang T. M. S. Experience with the treatment of acute liver failure patients by hemoperfusion over biocompatible microencapsulated (coated) charcoal // Artificial Liver Support / I. M. Murray-Lyon (eds), R. Williams. England. Tunbridge Wells: Pitman Medical, 1975. 367 p.

24. Chen G., Palmer A. F. Hemoglobin-based oxygen carrier and convection enhanced oxygen transport in a hollow fiber bioreactor // Biotechnol. Bioeng. 2009. Vol. 102. P. 1603–1612.

25. Chen G., Palmer A. F. Mixtures of hemoglobin-based oxygen carriers and perfluorocarbons exhibit a synergistic effect in oxygenating hepatic hollow fiber bioreactors // Biotechnol. Bioeng. 2010. Vol. 105. P. 534–542.

26. Chen G., Palmer A. F. Perfluorocarbon facilitated O2 transport in a hepatic hollow fiber bioreactor // Biotechnol. Prog. 2009. Vol. 25. P. 1317–1321.

27. Clinical application of bioartificial liver support systems / M. P. van de Kerkhove [et al.] // Ann. Surg. 2004. Vol. 240. P. 216–230.

28. Clinical extracorporeal hybrid liver support-phase I study with primary porcine liver cells / I. M. Sauer [et al.] // Xenotransplantation. 2003. Vol. 10. P. 460–469.

29. Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells / O. Parolini [et al.] // Stem. Cells. 2008. Vol. 26. P. 300–311.

30. Cowan P. J., d’Apice A. J. The coagulation barrier in xenotransplantation: incompatibilities and strategies to overcome them // Curr. Opin. Organ. Transplant. 2008. Vol. 13 P. 178–183.

31. Cultivation of immortalized human hepatocytes HepZ on macroporous CultiSpher G microcarriers / A. Werner [et al.] // Biotechnol. Bioeng. 2000. Vol. 68. P. 59–70.

32. Dan Y. Y., Yeoh G. C. Liver stem cells: a scientific and clinical perspective // J. Gastroenterol. Hepatol. 2008. Vol. 23. P. 687–698.

33. Demetriou A. A. Hepatic assist devices // Panminerva Med. 2005. Vol. 47. P. 31–37.

34. Development of a bioartificial liver: Properties and function of a hollow-fiber module inoculated with liver cells / J. Rozga [et al.] // Hepatology. 1993. Vol. 17. P. 258.

35. Differentiating characterization of human umbilical cord blood-derived mesenchymal stem cells in vitro / X. Q. Kang [et al.] // Cell .Biol. Int. 2006. Vol. 30. P. 569–575.

36. Differentiation and transplantation of human induced pluripotent stem cell- derived hepatocyte-like cells / S. Asgari [et al.] // Stem. Cel.l Rev. 2013. Vol. 9 (4). P. 493–504. DOI 10.1007/s 12015-011-9330y

37. Differentiation of human adipose stromal cells into hepatic lineage in vitro and in vivo / M. J. Seo [et al.] // Biochem. Biophys. Res. Commun. 2005. Vol. 328. P. 258–264.

38. Differentiation of human embryonic stem cells into hepatocytes in 2D and 3D culture systems in vitro / H. Baharvand [et al.] // Int. J. Dev. Biol. 2006. Vol. 50. P. 645–652.

39. Differentiation of human umbilical cord mesenchymal stromal cells into low immunogenic hepatocyte-like cells / Q. Zhao [et al.] // Cytotherapy. 2009. Vol. 11. P. 414–426.

40. Differentiation of mesenchymal cells derived from human amniotic membranes into hepatocyte-like cells in vitro / T. Tamagawa [et al.] // Hum. Cell. 2007. Vol. 20. P. 77–84.

41. Ding Y. T., Shi X. L. Bioartificial liver devices: Perspectives on the state of the art // Front. Med. 2011. Vol. 5. P. 15–19.

42. Donato M. T., Castell J. V., Gómez-Lechón M. J. Characterization of drug metabolizing activities in pig hepatocytes for use in bioartificial liver devices: comparison with other hepatic cellular models // J. Hepatol. 1999. Vol. 31. P. 542–549.

43. Early clinical experience with a hybrid bioartificial liver / A. A. Demetriou [et al.] // Scand. J. Gastroenterol. 1995 (Suppl). Vol. 208. P.111–117.

44. Early experiences with a porcine hepatocyte-based bioartificial liver in acute hepatic failure patients / E. Morsiani [et al.] // Int. J. Artif. Organs. 2002. Vol. 25. P. 192–202.

45. Effect of human patient plasma ex vivo treatment on gene expression and progenitor cell activation of primary human liver cells in multi-compartment 3D perfusion bioreactors for extra-corporeal liver support / E. Schmelzer [et al.] // Biotechnol. Bioeng. 2009. Vol. 103. P. 817–827.

46. Effect of human umbilical cord blood-derived mesenchymal stem cells in a cirrhotic rat model / K. H. Jung [et al.] // Liver Int. 2009. Vol. 29. P. 898–909.

47. Effects of artificial liver support system on patients with acute or chronic liver failure / W. B. Du [et al.] // Transplant. Proc. 2005. Vol. 37. P. 4359–4364.

48. Enhanced functions of human embryonic stem cell-derived hepatocyte-like cells on three-dimensional nanofibrillar surfaces / Z. Farzaneh [et al.] // Stem. Cell. Rev. 2010. Vol. 6 P. 601–610.

49. Establishment of a highly differentiated immortalized human hepatocyte cell line as a source of hepatic function in the bioartificial liver / N. Kobayashi [et al.] // Transplant. Proc. 2000. Vol. 132. P. 237–241.

50. Evaluation of a new immortalized human fetal liver cell line (cBAL111) for application in bioartificial liver / P. P. Poyck [et al.] // J. Hepatol. 2008. Vol. 48. P. 266–275.

51. Ex vivo characteristics of human amniotic membranederived stem cells / J. Kim [et al.] // Cloning Stem Cells. 2007. Vol. 9. P. 581–594.

52. Extracorporeal bioartificial liver using the radial-flow bioreactor in treatment of fatal experimental hepatic encephalopathy / H. Kanai [et al.] // Artif. Organs. 2007. Vol. 31. P. 148–151.

53. Fausto N. Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells // Hepatology. 2004. Vol. 39. P. 1477–1487.

54. First clinical use of a novel bioartificial liver support system (BLSS) / G. V. Mazariegos [et al.] // Am. J. Transplant. 2002. Vol. 2. P. 260–266.

55. Formation of multicellular spheroids composed of adult rat hepatocytes in dishes with positively charged surfaces and under other nonadherent environments / N. H. Koide [et al.] // Exper. Cell. Res. 1990. Vol. 186. P. 227.

56. Hay P. D., Veitch A. R., Gaylor J. D. Oxygen transfer in a convection-enhanced hollow fiber bioartificial liver // Artif. Organs. 2001. Vol. 25. P. 119–130.

57. Hepatic differentiation from human mesenchymal stem cells on a novel nanofiber scaffold / M. Ghaedi [et al.] // Cell. Mol. Biol. Lett. 2012. Vol. 17. P. 89–106.

58. Hepatic differentiation of amniotic epithelial cells / F. Marongiu [et al.] // Hepatology. 2011. Vol. 53. P. 1719–1729.

59. Hepatic stem cells: from inside and outside the liver? / M. R. Alison [et al.] // Cell. Prolif. 2004. Vol. 37. P. 1–21.

60. Hepatogenesis of adipose-derived stem cells on polylactidecoglycolide scaffolds: in vitro and in vivo studies / M. Wang [et al.] // Tissue. Eng. Part. C. Methods. 2010. Vol. 16. P. 1041–1050.

61. Hepatogenic differentiation of human mesenchymal stem cells from adipose tissue in comparison with bone marrow mesenchymal stem cells / R. Taléns-Visconti [et al.] // World J. Gastroenterol. 2006. Vol. 12. P. 5834–5845.

62. Human hepatocyte functions in a crossed hollow fiber membrane bioreactor / L. De Bartolo [et al.] // Biomaterials. 2009. Vol. 30. P. 2531–2543.

63. Human umbilical cord matrix stem cells efficiently rescue acute liver failure through paracrine effects rather than hepatic differentiation / S. Zhang [et al.] // Tissue. Eng. Part. A. 2012. Vol. 18. P. 1352–1364.

64. In vitro assessment of encapsulated C3A hepatocytes functions in a fluidized bed bioreactor / B. David [et al.] // Biotechnol. Prog. 2004. Vol. 20. Р. 1204–1212.

65. In vitro differentiation of human umbilical cord bloodderived mesenchymal stem cells into hepatocyte-like cells / S. H. Hong [et al.] // Biochem. Biophys. Res. Commun. 2005. Vol. 330. P. 1153–1161.

66. In vitro hepatic differentiation of human mesenchymal stem cells / K. D. Lee [et al.] // Hepatology. 2004. Vol. 40. P. 1275–1284.

67. In vivo hepatic differentiation of mesenchymal stem cells from human umbilical cord blood after transplantation into mice with liver injury / J. Yu [et al.] // Biochem. Biophys. Res. Commun. 2012. Vol. 422. P. 539–545.

68. In-depth physiological characterization of primary human hepatocytes in a 3D hollow-fiber bioreactor / D. Mueller [et al.] // J. Tissue. Eng. Regen. Med. 2011. Vol. 5. P. e207–218.

69. Induced pluripotent stem cells: a new era for hepatology / S. Asgari [et al.] // J. Hepatol. 2010. Vol. 53. Р. 738–751.

70. Inducing proliferation of human amniotic epithelial (HAE) cells for cell therapy / S. Terada [et al.] // Cell. Transplant. 2000. Vol. 9. P. 701–704.

71. Initial experience with the modified extracorporeal liver-assist device for patients with fulminant hepatic failure: system modifications and clinical impact / J. M. Millis [et al.] // Transplantation. 2002. Vol. 74. P. 1735–1746.

72. Isolation and characterization of a stem cell population from adult human liver / M. B. Herrera [et al.] // Stem. Cells. 2006. Vol. 24. P. 2840–2850.

73. Isolation and characterization of adult human liver progenitors from ischemic liver tissue derived from therapeutic hepatectomies / H. Stachelscheid [et al.] // Tissue. Eng. Part. A. 2009. Vol. 15. P. 1633–1643.

74. Isolation and characterization of stem cells from the placenta and the umbilical cord / C. M. Mihu [et al.] // Rom. J. Morphol. Embryol. 2008. Vol. 49. P. 441–446.

75. Isolation of human progenitor liver epithelial cells with extensive replication capacity and differentiation into mature hepatocytes / H. Malhi [et al.] // J. Cell. Sci. 2002. Vol. 115. P. 2679–2688.

76. Isolation of multipotent mesenchymal stem cells from umbilical cord blood / O. K. Lee [et al.] // Blood. 2004. Vol. 103. P. 1669–1675.

77. Isolation, characterization, and differentiation to hepatocytelike cells of nonparenchymal epithelial cells from adult human liver / C. Duret [et al.] // Stem. Cells. 2007. Vol. 25. P. 1779–1790.

78. Jauregui H. O., Muller T. E. Long-term cultures of adult mammalian hepatocytes in hollow fibers as the cellular component of extracorporeal (hybrid) liver assist devices // Artif. Organs. 1992. Vol. 16 (2). P. 209.

79. Jauregui H. O. Treatment of hepatic insufficiency based on cellular therapies // Int. J. Artif. Organs. 1991. Vol. 14. P. 407.

80. Jung Y., Bauer G., Nolta J. A. Concise review: Induced pluripotent stem cell-derived mesenchymal stem cells: progress toward safe clinical products // Stem. Cells. 2012. Vol. 30. P. 42–47.

81. Large-pore hemodialytic procedures in pigs with ischemic hepatic necrosis; a randomized study / G. H. De Groot [et al.] // Hepato-gastroenterology. 1984. Vol. 31 (6). P. 254–260.

82. Liver support systems / A. Santoro [et al.] // Contrib. Nephrol. 2007. Vol. 156. P. 396–404.

83. Manufacturing of human placenta-derived mesenchymal stem cells for clinical trials / G. Brooke [et al.] // Br. J. Haematol. 2009. Vol. 144. Р. 571–579.

84. Matikainen T., Laine J. Placenta-an alternative source of stem cells // Toxicol. Appl. Pharmacol. 2005. Vol. 207. P. 544–549.

85. McKenzie T. J., Lillegard J. B., Nyberg S. L. Artificial and bioartificial liver support // Semin. Liver. Dis. 2008. Vol. 28. P. 210–217.

86. Miki T., Ring A., Gerlach J. Hepatic differentiation of human embryonic stem cells is promoted by three-dimensional dynamic perfusion culture conditions // Tissue. Eng. Part. C. Methods. 2011. Vol. 17. P. 557–568.

87. Mullon C., Pitkin Z. The HepatAssist bioartificial liver support system: clinical study and pig hepatocyte process // Expert. Opin. Investig. Drugs. 1999. Vol. 8. P. 229–235.

88. Naik S., Santangini H., Jauregui H. O. Culture of adults rabbit hepatoctyes in perfused hollow membranes // In Vitro Cell. Dev. Biol. 1990. Vol. 26. P. 107.

89. Neonatal hepatocyte culture on artificial capillaries: A model for drug metabolism and the artificial liver / J. C. Hager [et al.] // ASAIO. J. 1983. Vol. 6. P. 26–35.

90. Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation / D. Samuel [et al.] // Transplantation. 2002. Vol. 73. P. 257–264.

91. Novel bioartificial liver support system: preclinical evaluation / J. F. Patzer [et al.] // Ann. N. Y. Acad. Sci. 1999. Vol. 875. P. 340–352.

92. Origin and characterization of a human bipotent liver progenitor cell line / R. Parent [et al.] // Gastroenterology. 2004. Vol. 126. P. 1147–1156.

93. Phase I clinical trial with the AMC-bioartificial liver / A. Belli [et al.] // Int. J. Artif. Organs. 2002. Vol. 25. P. 950–959.

94. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure / A. J. Ellis [et al.] // Hepatology. 1996. Vol. 24. P. 1446–1451.

95. Pitkin Z., Mullon C. Evidence of absence of porcine endogenous retrovirus (PERV) infection in patients treated with a bioartificial liver support system // Artif. Organs. 1999. Vol. 23. P. 829–833.

96. Pless G. Artificial and bioartificial liver support // Organogenesis. 2007. Vol. 3. P. 20–24.

97. Polson J., Lee W. M. American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure // Hepatology. 2005. Vol. 41 P. 1179–1197.

98. Primary cultures of rat hepatocytes in hollow fiber chambers / H. O. Jauregui [et al.] // In Vitro Cell. Dev. BIol. 1994. Vol. 30A. P. 23–29.

99. Progress and future challenges in stem cell-derived liver technologies / D. M. Dalgetty [et al.] // Am. J. Physiol. Gastrointest. Liver. Physiol. 2009. Vol. 297. P. G241–248.

100. Prolongation of survival of pigs with ischemic liver failure by treatment with a bioartificial liver using glutamine synthetase transfected recombinant HepG2 / S. Enosawa [et al.] // Transplant. Proc. 2001. Vol. 33. P. 1945–1947.

101. Promoter-defined isolation and identification of hepatic progenitor cells from the human fetal liver / P. Wang [et al.] // Histochem. Cell. Biol. 2008. Vol. 130. P. 375–385.

102. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure / A. A. Demetriou [et al.] // Ann. Surg. 2004. Vol. 239. P. 660–667.

103. Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol / Y. F. Chen // Hepatology. 2012. Vol. 55. P. 1193–1203.

104. Recovery of preservation-injured primary human hepatocytes and nonparenchymal cells to tissue like structures in large-scale bioreactors for liver support: an initial transmission electron microscopy study / J. C. Gerlach [et al.] // J. Invest. Surg. 2003. Vol. 16. P. 83–92.

105. Remy B., Deby-Dupont G., Lamy M. Red blood cell substitutes: fluorocarbon emulsions and haemoglobin solutions. // Br. Med. Bull. 1999. Vol. 55. P. 277–298.

106. Reprogramming of human somatic cells to pluripotency with defined factors / I. H. Park [et al.] // Nature. 2008. Vol. 451. P. 141–146.

107. Reversal of fulminant hepatic failure using an extracorporeal liver assist device / N. L. Sussman [et al.] // Hepatology. 1992. Vol. 16. P. 60.

108. Rozga J. Liver support technology – an update // Xenotransplantation. 2006. Vol. 13. P. 380–389.

109. Safety observations in phase I clinical evaluation of the Excorp Medical Bioartificial Liver Support System after the first four patients / G. V. Mazariegos [et al.] // ASAIO J. 2001. Vol. 47. P. 471–475.

110. Schäffler A., Büchler C. Concise review: adipose tissue-derived stromal cells-basic and clinical implications for novel cell-based therapies // Stem. Cells. 2007. Vol. 25. P. 818–827.

111. Schmelzer E., Wauthier E., Reid L. M. The phenotypes of pluripotent human hepatic progenitors // Stem. Cells. 2006. Vol. 24. P. 1852–1858.

112. Seghatchian J., de Sousa G. An overview of unresolved inherent problems associated with red cell transfusion and potential use of artificial oxygen carriers and ECO-RBC: current status/future trends // Transfus. Apher. Sci. 2007. Vol. 37. P. 251–259.

113. Separation of parenchymal liver cells using a lactosesubstituted styrene polymer substratum / T. Akaike [et al.] // J. Bioact. Compat. Polym. 1989. Vol. 4 (51).

114. Shi L. L., Liu F. P., Wang D. W. Transplantation of human umbilical cord blood mesenchymal stem cells improves survival rates in a rat model of acute hepatic necrosis // Am. J. Med. Sci. 2011. Vol. 342. P. 212–217.

115. Strain A. J., Neuberger J. M. A bioartificial liver – state of the art // Science. 2002. Vol. 295. P. 1005–1009.

116. TECA hybrid artificial liver support system in treatment of acute liver failure / Y. L. Xue [et al.] // World J. Gastroenterol. 2001. Vol. 7. P. 826–829.

117. The HepaRG cell line is suitable for bioartificial liver application / R. Hoekstra [et al.] // Int. J. Biochem. Cell. Biol. 2011. Vol. 43. P. 1483–1489.

118. The Hepatix extracorporeal liver assist device: initial clinical experience / N. L. Sussman [et al.] // Artif. Organs. 1994. Vol. 18. P. 390–396.

119. The promotion of hepatic maturation of human pluripotent stem cells in 3D co-culture using type I collagen and Swiss 3T3 cell sheets / Y. Nagamoto [et al.] // Biomaterials. 2012. Vol. 33. P. 4526–4534.

120. The significant improvement of survival times and pathological parameters by bioartificial liver with recombinant HepG2 in porcine liver failure model / S. Enosawa [et al.] // Cell. Transplant. 2006. Vol. 15. P. 873–880.

121. Toward a bioartificial drug metabolizing system: Gel immobilized liver cell microsomes / E. Denti [et al.] // Trans. Am. Soc. Artif. Intern. Organs. 1976. Vol. 22. P. 693–700.

122. Transdifferentiation of adipose-derived stem cells into hepatocytes: a new approach / J. Lue [et al.] // Liver Int. 2010. Vol. 30. P. 913–922.

123. Transplantation of human amnion epithelial cells reduces hepatic fibrosis in immunocompetent CCl4-treated mice / U. Manuelpillai [et al.] // Cell. Transplant. 2010. Vol. 19. P. 1157–1168.

124. Use of a rotary bioartificial liver in the differentiation of human liver stem cells / V. Fonsato [et al.] // Tissue. Eng. Part. C. Methods. 2010. Vol. 16. P. 123–132.

125. Use of primary human liver cells originating from discarded grafts in a bioreactor for liver support therapy and the prospects of culturing adult liver stem cells in bioreactors: a morphologic study / J. C. Gerlach [et al.] // Transplantation. 2003. Vol. 76. P. 781–778.

126. Zaehres H., Schöler H. R. Induction of pluripotency: from mouse to human // Cell. 2007. Vol. 131. P. 834–835.


Для цитирования:


Григорьев Е.В., Плотников Г.П., Шукевич Д.Л., Головкин А.С. БИОЛОГИЧЕСКАЯ ИСКУССТВЕННАЯ ПЕЧЕНЬ. Комплексные проблемы сердечно-сосудистых заболеваний. 2014;(4):70-79. https://doi.org/10.17802/2306-1278-2014-4-70-79

For citation:


Grigoryev E.V., Plotnikov G.P., Shukevich D.L., Golovkin A.S. BIOLOGICAL ARTIFICIAL LIVER. Complex Issues of Cardiovascular Diseases. 2014;(4):70-79. (In Russ.) https://doi.org/10.17802/2306-1278-2014-4-70-79

Просмотров: 180


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2306-1278 (Print)
ISSN 2587-9537 (Online)